Beyond synthetic controls: Near term-opportunities for regulatory RWE

Regulatory & Policy

Use of real-world evidence (RWE) in support of regulatory filings continues to be a key focus area among life sciences companies. As the field learns from regulator feedback about how RWE can meaningfully contribute to submissions, we begin to get a clearer picture of near-term opportunities for regulatory RWE. Hear from life science leaders about how their organizations have successfully applied RWE in recent regulatory submissions, as well as Flatiron’s evolving perspective on the use of RWE for regulatory use.


October 27, 2021

1:00 – 2:00pm ET

Live Q&A


Pranav Abraham BW Headshot

Pranav Abraham, PhD

Director, Global Health Economics, Rare Hematology

Bristol Myers Squibb

Lynn Howie  Headshot

Lynn Howie, MD

Medical Director

Flatiron Health

Kristin Sheffield BW Headshot

Kristin Sheffield, PhD

Research Advisor

Eli Lilly and Company

Chris Gayer BW Headshot

Christopher Gayer, PhD (Moderator)

Director of Product Management

Flatiron Health

Join the live presentations and discussions.
Register for ResearchX